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bstract
Breast cancer is the most common malignancy amongst women in the developed world. For patients with hormone-sensitive breast cancer
ligible for adjuvant hormonal therapy, it is important to know if the ovaries are (still) functional or not. Indeed, the choice for a specific
djuvant hormonal treatment depends on the menopausal status of an individual woman. The currently available measures to determine the
enopausal status are conflicting. Until better measures become available, we propose a practical guideline enabling an optimal choice of
djuvant hormonal therapy for women with a hormone receptor positive breast cancer taking into account uncertainties about their menopausal
tatus.
2012 Elsevier Ireland Ltd. All rights reserved.
l therap
r
t
t
w
a
2
2
a
u
W
v
i
s
w
m
p
p
c
f
f
f
b
d
(
d
f
i
p
o
e
m
i
ieywords: Hormone-sensitive breast cancer; Menopausal status; Hormona
. Introduction
Breast cancer is the most common malignancy among
omen, with a prevalence of almost 207,090 individuals
n the United States in 2010. It is after colorectal can-
er the second most common cause of cancer death in
omen, with an estimated 39,840 deaths in the same year [1].
ver the years, breast cancer mortality has declined partly
ue to the implementation of surveillance programs lead-
ng to early detection, and partly due to improved treatment
odalities. One of these modalities consists of adju-
ant endocrine therapy for hormone-sensitive breast cancer
atients.
The choice for a specific hormonal treatment depends
n the menopausal status of the patient. In postmenopausal
atients, adjuvant hormonal treatment with an aromatase
nhibitor (AI) given upfront or tamoxifen followed by an AI
as proven to be superior to tamoxifen alone and therefore
as become standard of care [2–5]. In contrast, in clearly
remenopausal women adjuvant treatment with tamoxifen
ith or without ovarian suppression is recommended [6–9].
randomized clinical trial comparing adjuvant ovarian sup-
ression in combination with tamoxifen or anastrozole with
r without zoledronic acid in premenopausal women with
reast cancer who were not treated with chemotherapy has
hown no superiority of an AI over tamoxifen in this artifi-
ially postmenopausal setting [10].
While tamoxifen can be safely given to premenopausal
omen, this is not the case for AIs. AIs interfere with
he conversion of androgens into estrogens by blocking
he enzyme aromatase resulting in low estradiol levels in
ruly postmenopausal women [11]. However, in the pres-
nce of (still) functional ovaries, low levels of estrogen will
nhance pituitary FSH production indirectly stimulating the
ollicular production of aromatase and subsequently of estra-
iol. As a consequence, categorizing premenopausal women
naccurately as postmenopausal and treating them with AIs
ithout co-treatment with a gonadotropin-releasing hormone
GnRH) agonist may be ineffective. Moreover, in case of
hemotherapy induced amenorrhoea (CIA) AIs may promote
ecovery of ovarian function which could lead to therapeutic
ailure and even to unwanted pregnancy [12]. On the other
and, treatment with GnRH agonists may be accompanied
ith additional side effects and is costly [13].
t
a
dy
In this review we will describe the physiology of natural
eproductive aging, summarize the current methods to assess
he menopausal status and propose a practical guideline for
he optimal choice of adjuvant hormonal therapy for women
ith a hormone receptor positive breast cancer taking into
ccount uncertainties about the exact menopausal status.
. Menopausal status
.1. Physiology of natural reproductive aging
The nomenclature for the different phases of reproductive
ging has been inconsistent and confusing. In an attempt to
niform this nomenclature, the Stages of Reproductive Aging
orkshop (STRAW) has developed a staging system pro-
iding useful clinical definitions of the reproductive stages
ncluding menopausal transition, perimenopause, final men-
trual period, menopause, and post-menopause for healthy
omen aging to a natural menopause [14] (Fig. 1).
Folliculogenesis refers to the process during which pri-
ordial follicles are continuously recruited out of the
rimordial follicle pool. Recruited follicles develop via the
rimary, secondary and tertiary stages into antral (antrum
ontaining) follicles [15] (Fig. 2). Up to a diameter of 10 mm
ollicle development is gonadotropin independent. After one
ollicle has been selected out of a small cohort of antral
ollicles measuring between 8 and 10 mm, this follicle will
ecome the dominant follicle. From this stage, final follicle
evelopment is dependent on follicle-stimulating hormone
FSH). The final maturation steps preceding ovulation are
riven by FSH and luteinizing hormone (LH). Hence, final
ollicle development coincides with the onset of menses dur-
ng which FSH levels are elevated. The 14-days follicular
hase of the menstrual cycle represents the development
f a late antral follicle into a pre-ovulatory follicle. At the
nd of this phase ovulation preludes the luteal phase of this
enstrual cycle which takes another 14 days (Fig. 2). It is
mportant to realize that the whole process lasts for approx-
mately 360 days which is also roughly in accordance with
he duration of the period between the final menstrual period
nd menopausal transition [16,17].
Ovaries of a newborn girl harbor about 1 million primor-
ial follicles each. Due to a continuous process of atresia,
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Terminology postmenopause menopausal transition premenopausal 
perimenopause 
Folliculogenesis present diminished complete absent 
Final menstrual period  = end of 
estradiol production by the ovaries 
Menopause = anchor point defined as 12 months of 
amenorrhea after the final menstrual period 
Fig. 1. Terminology of the different stages of the menopausal transition and the corresponding function of folliculogenesis.
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he majority of primordial follicles will be lost. At puberty,
he total number per ovary has dropped to approximately
00,000–400,000. During a women’s reproductive period
nly about 400 of these will eventually ovulate, while most
ollicles will disappear through atresia involving the process
f apoptosis. At menopause, there is a nearly complete deple-
ion of primordial follicles. With advanced age, decreasing
umber of oocytes and declining oocyte quality cause even-
ually the termination of estradiol production by the ovaries.
he “final menstrual period” can only be defined in retro-
pect, i.e. after 12 months of amenorrhea. The average age
f menopause in women of Caucasian/European origin is
round 51 years of age, but can range from 40 up to 60 years
18].
a
c
md menstrual cycle.
.2. Defining menopausal status in breast cancer
atients
In general, three groups of women can safely be consid-
red postmenopausal; all women older than the age of 60,
omen who underwent a bilateral ovariectomy, and women
ounger than 60 years not using oral contraceptives or hor-
one replacement therapy (HRT) with an intact uterus and
eing amenorrheic for at least one year prior to the diagno-
is of breast cancer. Women having regular menses/periods
ithout using oral contraceptives or HRT can be classifieds premenopausal. Strictly stated, remaining ovarian activity
annot be excluded for all other women and therefore the
enopausal status is then uncertain.
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.2.1. Chemotherapy induced amenorrhea (CIA)
Ascertainment of the menopausal status of breast cancer
atients may be more complicated by the effect of anticancer
herapy on functional ovarian reserve. Patients may develop
IA that could be transient. Bines et al. proposed to define
IA as secondary amenorrhea of >6 months in a patient being
re- or peri-menopausal before the start of chemotherapy
19]. However, an amenorrheic period after chemotherapy
f even more than one year in a patient with an intact uterus
ight not exclude resumption of menses.
The effect of chemotherapy on the ovaries may consist of
irect destruction of remnant functional follicles or induction
f ovarian fibrosis with a total disappearance of functional
ollicles. On the other hand, chemotherapy could also lead
o CIA by inducing primary or hypergonadotropic hypogo-
adism, as observed by low levels of estradiol and high levels
f FSH and LH [19]. As long as treatment does not contain
igh dose of glucocorticoids, depressing ACTH production,
he pituitary function seems not affected by chemotherapy.
The induction of CIA mainly depends on the age at admin-
stration and type of chemotherapy administrated. In general,
atients above the age of 40 years have a far greater risk
f developing CIA without recovery of ovarian function
77–100%) compared with patients below the age of 40 years
0–40%), irrespective whether alkylating- or anthracycline-
ontaining chemotherapy has been administered [12,20,21].
he wide range in risk for permanent CIA in women older
han 40 years mentioned in the literature may relate to vari-
bility of age groups, lack of consistent CIA definition and
ifferent hormonal treatment strategies used in the various
retrospective) trials. Although occurrence and duration of
IA was not influenced by tamoxifen, use of AIs induced a
ecovery of ovarian function in 27% compared to historical
–11% of women older than 40 years [12,20].
In view of the abovementioned, it may be clear that assess-
ng the actual functionality of the remaining ovarian tissue in
reast cancer patients eligible for adjuvant endocrine ther-
py is of utmost importance and challenging. The question is
hether the blood levels of hormones and/or growth factors,
ecreted in the different stages of the folliculogenesis, could
e of help to define the start of the menopause.
. Biomarkers for assessment of menopausal status
.1. Conventional biomarkers
.1.1. Follicle-stimulating hormone (FSH)
Levels of FSH combined with levels of estradiol are often
sed to define the menopausal status of women before and
fter treatment with chemotherapy, although these deter-
inations are far from ideal. FSH is produced by thenterior pituitary gland, by pulsatile releases of gonadotropin
eleasing hormone from the hypothalamus. In women, FSH
timulates the growth of the small antral follicles and finally
auses selection of the follicle having the most FSH receptors
s
i
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hich then will become the dominant pre-ovulatory follicle
15,17] (Fig. 2). Follicular cells of developing pre-ovulatory
ollicles, also called granulosa cells, produce considerable
mounts of estradiol which in turn exerts a negative feedback
t the level of the pituitary hypothalamus and consequently
SH levels decrease. Elevated blood FSH levels reflect an
ge-dependent decrease in the follicle pool. Therefore, in
ime the number of follicles with properly functioning granu-
osa cells will decline and hence estradiol levels will decrease.
onsequently FSH levels will rise. The so-called monotropic
ise in FSH levels is the latest hormonal event preceding
enopause. However, the elevation of FSH may already
ccur approximately 3–8 years before menopause, at least in
he presence of anovulatory cycles [22,23]. As the FSH lev-
ls rise above 20 IU/L during the late perimenopausal phase,
his is often used as the cut-off value to determine deple-
ion of ovarian reserve [22–24]. However, treatment with
amoxifen in truly postmenopausal women may induce a
ecrease in FSH levels, even into the premenopausal range
25]. Conversely, chemotherapy-induced amenorrhea in pre-
enopausal women may result in highly increased FSH
evels which can be temporarily and as such is no guarantee
or absence of folliculogenesis in the future [24]. Therefore,
o absolute cut-off level of FSH can be given above which
olliculogenesis does not occur anymore.
.1.2. Estradiol
Estradiol is mainly secreted by the late antral follicle and
he ensuing corpus luteum, controlled by FSH and LH [15].
nce the ovarian secretion of estradiol is absent, the blood
evels of estradiol depend predominantly on the conversion of
ndrostenedione–testosterone to estradiol by the aromatase
nzyme in abdominal/peripheral fat and other tissues. It has
een reported that estradiol levels lower than 130 pmol/L can
e considered as postmenopausal levels, but values between
0 and 60 pmol/L have been reported as well [12,22,23]. Also,
stradiol levels may be highly variable in postmenopausal
omen, as this is influenced by obesity/body mass index
BMI) and smoking habits [22,23]. Estradiol levels are higher
n obese postmenopausal women due to an increased num-
er of adipose cells and, therefore, relatively more aromatase
ctivity, while nicotine and its metabolite cotinine are strong
nhibitors of aromatase leading to lower levels of estradiol
evels among smokers [26,27]. Finally, HRT might lower
SH and increase estradiol levels up to one year after ces-
ation of therapy [28].
It is also important to mention that the accuracy of com-
ercially available methods for determination of estradiol
evels is largely variable. Most clinical assays in use are
utomated or kit-based immunoassays. Extraction and purifi-
ation of estradiol from plasma are frequently skipped in
he quantification process, as speed, ease of analysis and
mall sample volume were the preferred variables focus-
ng on premenopausal estradiol levels of 100–1200 pmol/L.
ompetition between sex hormone binding globulin and the
stradiol antibody used in these assays and the presence of
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ater-soluble conjugated steroid concentrations lead to vari-
ble estradiol levels with an increasing risk for overestimating
he estradiol concentration, especially in patients with low
evels. Routine use of direct estrogen assays for control of
I treatment compliance is not recommended, as increased
re-aromatization steroid concentrations by inhibition of the
nzyme may bias the results. Accuracy of measuring lower
stradiol levels would be improved largely by immunoassays
ncluding an extraction step or tandem gas chromatography
nd mass spectrometry assays [29]. Further improvement of
adioimmunoassays led to a lower detection level of estradiol
0.67 pmol/L), useful in postmenopausal women and women
reated with AIs [30].
Thus, there is no clear cut-off level of estradiol which
redicts the complete absence of folliculogenesis.
.2. Possible new biomarkers to assess menopausal
tatus
To assess menopausal status more accurately, it is rational
o search for a hormone or a growth factor which is solely
roduced by the follicles during the early stages of the fol-
iculogenesis (i.e. the primordial or primary follicles) and not
nly by follicles that have advanced to more mature stages.
heoretically, such a ‘marker’ will be undetectable if the pri-
ordial follicle pool is completely exhausted. This would
remendously facilitate the assessment of the menopausal sta-
us. Two possible candidates have been proposed: inhibin B
nd anti-Müllerian hormone (AMH).
.2.1. Inhibins
Inhibins are members of the TGF- superfamily and com-
osed of an - and -subunit forming inhibin A or inhibin B,
espectively [15] (Fig. 2). Like estradiol, inhibin A is secreted
y pre-ovulatory follicles and the corpus luteum and, there-
ore, a less plausible predictive marker for ovarian reserve.
nhibin B is produced by early antral follicles. With a dwin-
ling number of antral follicles in the late perimenopause,
nhibin B levels begin to drop and, therefore, might be a
ood marker of ovarian reserve [28,31]. However, inhibin
levels are not constant during the menstrual cycle; i.e. they
ncrease during the early follicular phase and decrease dur-
ng the late follicular and early luteal phase following FSH
eedback. Furthermore, serum inhibin B levels are already
ndetectable about 4 years prior to the final menstrual period
32,33]. Inhibin B has been investigated in a single study
n 127 premenopausal, early breast cancer patients who were
reated with chemotherapy [34]. Compared with age-matched
ontrols, chemotherapy treated cancer subjects had signif-
cantly lower inhibin B levels (p = 0.001). Inhibin B was
ignificantly associated with risk of CIA, even after control-
ing for FSH. These levels could possibly predict whether the
varian reserve before the start of chemotherapy is sufficient
o survive the chemotherapy induced loss of follicles. Fur-
her research in this field is warranted in order to obtain more
nformation hereon.
o
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.2.2. Anti-Müllerian hormone
AMH, also known as Müllarian inhibiting substance, is
member of the transforming growth factor-beta (TGF-
) superfamily and is produced by the pool of primary,
econdary and early antral follicles (Fig. 2). Levels of
MH, undetectable during the first years after birth in
irls, rise sharply during puberty when folliculogenesis starts
nd remains relatively unchanged throughout the menstrual
ycles [35,36]. This is mainly due to the fact that, in con-
rast to estradiol, AMH does not exert any feedback on the
ypothalamic–pituitary–ovarian axis [37,38].
The two main functions of AMH are: (1) inhibition of
ecruitment of primordial follicles; and (2) inhibition of FSH
ensitivity of late antral follicles. As the pool of primor-
ial follicles diminishes with aging, the follicle pool that
ecretes AMH decreases. As a consequence, lower levels
f AMH will increase the rate of recruitment of primordial
ollicles, resulting in an acceleration of the depletion of the
rimordial follicle pool toward the end of the reproductive
eriod. Therefore, reduced AMH levels could be an excel-
ent early marker for ovarian reserve through the menopausal
ransition. In a recently published long-term follow-up study
f normo-ovulatory women (age 21–46 yr), age-specific
MH levels indeed were highly predictive for timing the
enopause [37].
Despite the potential of AMH as a marker of menopause
everal challenges remain. Although the currently available
nzyme-immunometric assays are highly sensitive (detection
evel 0.05 ng/ml), the lowest level of detection is still not an
bsolute cut-off level marking the menopause precisely [37].
oreover, the effect of chemotherapy on and the interpreta-
ion of the AMH levels are still unclear. In the previously
entioned study by Su et al., breast cancer patients with
tage I to III disease who were premenopausal at diagno-
is and were enrolled post-chemotherapy, had significantly
ower AMH levels compared to age-matched controls [34].
ow AMH levels of treated patients were significantly associ-
ted with the risk of CIA, also after controlling for FSH. Only
wo observational studies prospectively investigated AMH up
o one year after the end of adjuvant chemotherapy in pre-
enopausal breast cancer patients [39,40]. In the first study,
fty premenopausal women (age range 28–52 years) with
arly breast cancer were included [39]. Pretreatment, AMH
oncentrations were lower with increasing age even before
hanges in other hormone concentrations occurred. AMH
oncentration showed a rapid and marked fall during the
hemotherapy period, reaching undetectable concentrations
n many women (p < 0.0001). The second study described
eventeen women undergoing chemotherapy (median age 30
ears; range 19–35 years; eight diagnosed with breast can-
er) [40]. AMH levels dropped from 2.7 ± 1.0 to 1.1 ± 0.6
nd to 0.4 ± 0.4 ng/mL immediately after one and two cycles
f chemotherapy, respectively, suggesting that the gonado-
oxic effect of chemotherapy involves primary, secondary
nd early antral follicles. However, the AMH levels in most
atients subsequently rose approximately 8 months after the
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Patients with hormone sensitive breast cancer
CLEARLY PREMENOPAUSAL
=
regular ovarian cyclicity prior to breast 
cancer diagnosis without using oral 
contraceptives/HRT
UNCERTAIN MENOPAUSAL STATUS
= 
not falling within the definition of clearly 
pre- or clearly postmenopausal status
CLEARLY POSTMENOPAUSAL
=
older than 60 years OR
bilateral ovariectomy OR
amenorrhea >12 months prior to breast
cancer diagnosis without using oral 
contraceptives/HRT
5 YEARS TAMOXIFEN
OVARIAN SUPPRESSION IS  OPTIONAL 
SWITCH THERAPY or
5 YEARS UPFRONT AI
Discontinue use of oral contraceptives/HRT
START TAMOXIFEN WITHOUT OVARIAN 
SUPPRESSION
AND
monitor during 2,5-3 years
- menstrual cyclicity
- FSH, estradiol and AMH** levels
IF AFTER 2,5-3 YEARS
no >1 menstrual cycle and 
FSH >20 IU/L and
estradiol <110 pmol/L
AMH,if determined, should be <0.05 ng/mL  
IF WITHIN 2,5-3 YEARS
(ir)regular menstrual cycles
or one of the following:
- FSH ≤20 IU/L
- estradiol ≥110 pmol/L
AMH > 0.05 ng/mL supports a 
premenopasual status
SWITCH TO AI*
Fig. 3. Practical guideline for patients with hormone sensitive breast cancer with an indication for adjuvant hormonal therapy HRT, hormonal replacement
therapy; AMH, anti-Müllerian hormone; FSH, follicle stimulating hormone; AI, aromatase inhibitor. * It remains still important for this group that women
after starting AI should report reoccurrence of menses and/or declining of menopausal symptoms, with consequently measuring levels of FSH and estradiol
e facility
e
o
n
w
e
m
t
3
r
d
s
f
b
a
a
w
t
t
c
A
i
i
v
f
u
d
a
t
fi
n
4
e
i
e
g
c
4.g. every three months during one year. ** Only if local laboratory has the
nd of chemotherapy. Thus, a declined AMH level after start
f chemotherapy is not always permanent and as such can-
ot predict whether folliculogenesis will or will not recover
ithin the following year. Further research is needed to
xplore the exact predictive value of AMH levels in pre-
enopausal early breast cancer patients before, after and up
o at least one year after finishing adjuvant chemotherapy.
.3. Antral follicle count (AFC) by ultrasound
Ovarian reserve is related to the number and quality of
emaining primordial follicles. Unfortunately, these primor-
ial follicles are too small to be visualized by ultrasound. In a
tudy of 162 women (age 25–46 years) the number of antral
ollicles with a diameter between 2 and 10 mm was estimated
y ultrasound in the early follicular phase and was suggested
s a surrogate for ovarian reserve [41]. The number of small
ntral follicles in both ovaries as measured by ultrasound
as related to reproductive age and could be a reflection of
he size of the remaining primordial follicle pool. Similar
o results found in healthy women, AFC is highly positively
orrelated with AMH levels in breast cancer survivors [42].
FC was not an independent predictor of postmenopause
n normo-ovulatory women [37]. Moreover, reproducibil-
ty of AFC is influenced by inter-observer and inter-cycle
w
oto measure AMH.
ariability [41,43]. Finally, clinical use is hampered by the
act that AFC can only be assessed during the early follic-
lar phase, while it remains unclear when AFC should be
etermined in women with oligo- or amenorrhea. Also, it is
n elaborate and invasive (transvaginal) method to measure
he ovarian reserve repeatedly during the first two years after
nishing chemotherapy. Therefore, alternative methods are
eeded.
. Clinical guideline for breast cancer patients
ligible for adjuvant hormonal therapy
Given the difficulties as well as the relevance of determin-
ng the accurate menopausal status of breast cancer patients
ligible for adjuvant hormonal therapy, we propose a practical
uideline, based on the currently available evidence, without
ompromising the optimal hormonal treatment (Fig. 3).
.1. Adjuvant hormonal therapy in postmenopausal
omen
In patients clearly classified as postmenopausal at the start
f hormonal treatment (see Section 2.2), both switch therapy
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f 2–3 years of tamoxifen followed by 3–2 years of an AI or
pfront AI for 5 years are adequate options [2–5].
.2. Adjuvant hormonal therapy in premenopausal
omen
In clearly premenopausal women 5 years adjuvant treat-
ent with tamoxifen with or without ovarian suppression is
ecommended [6].
.3. Adjuvant hormonal therapy in women with
ncertain menopausal status
.3.1. Initial treatment (first 2.5–3 years)
For patients in whom the menopausal status cannot
et be determined as truly postmenopausal at the start of
ormonal treatment we propose to start tamoxifen with-
ut additional ovarian suppression. To date there is no
onvincing evidence for this particular group of mainly
lder pre- or perimenopausal women that adjuvant hor-
onal therapy with tamoxifen alone is inferior to tamoxifen
ith ovarian suppression, certainly after chemotherapy. A
eta-analysis comparing tamoxifen alone versus tamoxifen
ombined with a GnRH agonist in premenopausal patients
ith hormone-receptor positive breast cancer showed no sig-
ificant difference in disease-free and overall survival [44].
urthermore, in a large retrospective study no significantly
dditional benefit from adding GnRH to tamoxifen compared
o tamoxifen alone was observed, although in this study the
amoxifen dose was 40 mg daily and the adjuvant hormonal
herapy was ceased after 2 years [45]. At the Sankt Gallen
reast Cancer Conference 2011, only 37.5% of the expert
anel members favored combining ovarian suppression with
amoxifen to tamoxifen alone as adjuvant hormonal treatment
n this group of premenopausal women [7]. This strategy is
n line with the recently updated international guidelines of
SCO and NCCN recommending tamoxifen without ovarian
uppression as a valid option in older premenopausal breast
ancer patients [8,9]. Therefore, starting hormonal therapy
ith tamoxifen without ovarian suppression for 2–3 years
s a reasonable treatment option for patients with uncer-
ain menopausal status post chemotherapy, and provides the
pportunity to monitor the menopausal status within the fol-
owing 2–3 years. Also, withholding the administration of
nRH agonist is less expensive, and more convenient for
he patient. Of note, for patients younger than 40 years of
ge, a paucity of data is available supporting this general
vidence of equivalence between tamoxifen and tamoxifen
lus ovarian suppression. In fact, some data are in favor of
he combined modality for this group [46–48]. Therefore,
or patients younger than 40 years this guideline should be
nterpreted with caution.In contrast herewith, Ortmann et al. make a plea for incor-
orating AI treatment in pre-, peri- or postmenopausal breast
ancer patients as soon as possible [49]. E.g. in case of CIA
nd age ≥ 40 years they suggest to start with upfront AI,
t
e
t
iology/Hematology 84 (2012) 252–260
f estradiol and FSH levels, assessed by reliable and valid
easures, are in the postmenopausal range. Arguments in
avor of our conservative approach may be found in the
ecently published article on the long-term efficacy data of
he Austrian Breast and Colorectal Cancer Study Group trial-
2 (ABCSG-12) [50]. In this trial in premenopausal women
ith hormone-receptor positive early-stage (stage I–II) breast
ancer receiving goserelin (3.6 mg every 28 days) the efficacy
nd safety were compared of anastrozole (1 mg per day) or
amoxifen (20 mg per day) with or without zoledronic acid
or 3 years. At a median follow-up of 62 months there was
o difference in disease-free survival between patients on
amoxifen versus anastrozole, but overall survival was sig-
ificantly worse for anastrozole compared to tamoxifen (46
ersus 27 deaths; HR 1.75, 95% CI 1.08–2.83; p = 0.02).
hese data emphasize that tamoxifen is effective and safe, and
nderscore the use of tamoxifen in this patient group. More-
ver, the initial treatment with AIs (with or without GnRH
gonist) is not recommended for patients with an uncertain
enopausal status [6,12].
.3.2. Subsequent treatment (years 2.5–5)
The decision whether or not to switch to an AI should
e made after 2–3 years of adjuvant tamoxifen therapy,
epending on whether or not a definite postmenopausal
tatus has been attained. As discussed above, for the cur-
ently available biomarkers there is no specific cut off level
o be used to determine a postmenopausal status with cer-
ainty. For current clinical practice and the decision to switch
o an AI, we propose to use the re-occurrence of menses
uring the preceding two and a half year in combination
ith the results of serial measurements of FSH, estradiol
nd AMH levels (if the AMH measure is available). Since
isdiagnosing patients as being postmenopausal should be
voided, it is sensible to consider a conservative defini-
ion of postmenopausal status. Therefore, we propose the
ollowing definition for postmenopause: no more than one
enstrual period and FSH levels > 20 IU/L and estradiol lev-
ls in postmenopausal range according to the local laboratory
in general < 110 pmol/L) over the 2–3 years of tamoxifen
reatment [22–24]. In hospitals where the determination of
MH is available, we would advise to incorporate an AMH
evel < 0.05 ng/ml as an additional condition for defining
he postmenopause [40]. To increase accuracy, the deter-
ination of estradiol should preferably be performed by
sing immunoassays including an extraction step or tandem
as chromatography or by using mass spectrometry assays
29,30]. It should be noted that the predictive value of AMH
n order to asses menopausal status is based on two trials only
39,40].
Patients who meet the mentioned criteria can be consid-
red “truly” postmenopausal and be switched from tamoxifen
o an AI. After AI initiation, serial monitoring of FSH and
stradiol is strongly recommended for at least one year after
he start of AI administration. It still remains important to
nform the women to report reoccurrence of menses and/or
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ecline of menopausal symptoms, at which time levels of
SH and estradiol should be reassessed.
.3.3. Special consideration for obesity and hormonal
herapy
An increase in BMI leads to an increase in total-body
romatization and as a consequence, an increase in estra-
iol serum levels [51,52]. In other words BMI may serve
s a useful surrogate parameter for total-body aromatiza-
ion. As AIs inhibit the conversion of androgens to estrogens
hich occurs mainly in the peripheral apidose tissue, it is
onceivable that the efficacy of AIs is influenced by the
otal-body aromatization and thus the patient’s BMI [26,53].
oreover, there could be an effect of BMI on the relative
enefit of an AI versus tamoxifen.
Several retrospective studies have indeed suggested a non-
ignificant trend in a greater relative efficacy of AIs versus
amoxifen in non-obese compared to obese post-menopausal
atients [53,54]. Among premenopausal patients, the efficacy
f anastrozole plus goserelin compared to tamoxifen plus
oserelin was also non-significantly impaired (hazard rate
f disease free survival = 1.49 [range, 0.93–2.38]; p = 0.088)
mong those patients with a higher BMI (25–29.9 kg/m2).
he efficacy between the two treatment arms among normal
eighted patients was not different [55]. Thus, the choice of
djuvant hormonal therapy in obese breast cancer patients
s still a matter of debate. Prospective studies are urgently
eeded to clarify the precise efficacy of AIs in these patients.
. Conclusion
For patients with hormone sensitive breast cancer, knowl-
dge of the precise time point by which the ovarian reserve is
epleted is of great importance for the decision regarding the
ptimal adjuvant hormonal treatment. Unfortunately, the cur-
ently available measures to determine the postmenopausal
tatus are of limited reliability. Until better measures become
vailable, we proposed a practical guideline based on the
urrently existing scientific evidence (Fig. 3). To validate the
roposed guideline, we have set up a prospective follow-up
rial to assess AMH as a predictive tool for recovery of the
varian function following CIA.
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